ArticleJournal of translational medicine2025
Enhancing doxorubicin sensitivity in osteosarcoma via iRGD-modified biomimetic nanoparticles targeting MCAM m6A modification.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoparticle-based mechanistic and multifunctional strategies for targeted osteosarcoma therapy.Discover nano · 2026Review
- Advances in Nano-Drug Delivery Systems for Osteosarcoma: From Targeting Strategies to Combating Lung Metastasis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDoxorubicin (Dox) resistance remains a significant challenge in osteosarcoma (OS) treatment, limiting its therapeutic efficacy and contributing to poor clinical outcomes. This study aims to investigate the use of iRGD-modified biomimetic nanoparticles (NPs) for the targeted delivery of METTL3-specific inhibitors, addressing Dox resistance by regulating the m6A modification of MCAM.
methodsBiomimetic NPs were fabricated by fusing OS cell membranes with lipid NPs, followed by iRGD peptide modification to enhance tumor targeting capability. These NPs were loaded with the METTL3 inhibitor STM2457 and characterized for stability, drug encapsulation efficiency, and cellular uptake by Dox-resistant OS cells. Functional assays were implemented to examine their impact on cell biological functions in vitro. Therapeutic efficacy was further validated utilizing a mouse xenograft model to monitor tumor progression and metastatic behavior.
resultsThe iRGD-modified NPs exhibited excellent stability, high drug encapsulation efficiency, and significantly improved cellular uptake in vitro. METTL3 inhibition reduced MCAM m6A modification, leading to decreased proliferation and invasion of Dox-resistant OS cells. In vivo, the combination of Dox and METTL3-loaded NPs significantly inhibited tumor growth and lung metastasis in the mouse model.
conclusionsiRGD-modified biomimetic NPs offer a promising approach to overcoming Dox resistance in OS by targeting the METTL3-MCAM axis. This strategy may improve therapeutic outcomes and holds potential for clinical application in resistant cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.